Disability

KONZA National Network Joins Missouri eLTSS Project Phase 2 to Advance Person-Centered Care for Individuals with IDDKONZA National Network Joins Missouri eLTSS Project Phase 2 to Advance Person-Centered Care for Individuals with IDD

KONZA National Network Joins Missouri eLTSS Project Phase 2 to Advance Person-Centered Care for Individuals with IDD

TOPEKA, Kan., April 24, 2025 /PRNewswire/ -- KONZA National Network is proud to announce its partnership in Phase 2 of the…

2 months ago
Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing RoundAce Vision Group Announces Initial Close of $29.4 Million Series B Financing Round

Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round

Funding supports the commercial product development of VisioLite® Device and Laser Scleral Microporation Human Clinical Study. Capital raised to date…

2 months ago
CMA Physician Services unveils MedWay, a new administrative support service to help independent practices thriveCMA Physician Services unveils MedWay, a new administrative support service to help independent practices thrive

CMA Physician Services unveils MedWay, a new administrative support service to help independent practices thrive

New solution simplifies practice management, enhances efficiency, and preserves autonomy for healthcare providers. SACRAMENTO, Calif., April 22, 2025 /PRNewswire/ --…

2 months ago
Enlivex Announces Completion of Enrollment In The Phase II stage Of  Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee OsteoarthritisEnlivex Announces Completion of Enrollment In The Phase II stage Of  Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

2 months ago
Therabody Introduces Performance Team to Champion the Future of Sport and RecoveryTherabody Introduces Performance Team to Champion the Future of Sport and Recovery

Therabody Introduces Performance Team to Champion the Future of Sport and Recovery

The first six athletes are redefining what it means to push limits, build community, and prioritize recovery in their pursuit…

2 months ago
MYndspan Appoints Holmusk Founder and CEO Nawal Roy as Strategic AdvisorMYndspan Appoints Holmusk Founder and CEO Nawal Roy as Strategic Advisor

MYndspan Appoints Holmusk Founder and CEO Nawal Roy as Strategic Advisor

Following momentum from its Crowdcube campaign and investment from EMOTIV, MYndspan is deepening its commitment to evidence-based brain health LONDON,…

2 months ago
Ace Vision Group to Host “Take the Presbyopia Challenge” Event and Present Scientific Posters at 2025 ASCRS Annual MeetingAce Vision Group to Host “Take the Presbyopia Challenge” Event and Present Scientific Posters at 2025 ASCRS Annual Meeting

Ace Vision Group to Host “Take the Presbyopia Challenge” Event and Present Scientific Posters at 2025 ASCRS Annual Meeting

BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Ace Vision Group, Inc. (“AVG” or “the Company”), an emerging medical device company on…

2 months ago
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual MeetingAlterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected…

2 months ago
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual MeetingTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting…

2 months ago
NOVA’s Concierge Medicine Boom is a Game Changer for PatientsNOVA’s Concierge Medicine Boom is a Game Changer for Patients

NOVA’s Concierge Medicine Boom is a Game Changer for Patients

CHICAGO, April 10, 2025 /PRNewswire/ -- Home to some of the nation's most renowned hospitals and healthcare research centers, Northern…

2 months ago